Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: a focus on aducanumab and lecanemab

M Shi, F Chu, F Zhu, J Zhu - Frontiers in aging neuroscience, 2022 - frontiersin.org
Alzheimer's disease (AD) is the most prevalent form of age-related dementia in the world,
and its main pathological features consist of amyloid-β (Aβ) plaque deposits and …

Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches

D Kellar, S Craft - The Lancet Neurology, 2020 - thelancet.com
Insulin is a peptide secreted by the pancreas and plays an important role in the regulation of
glucose metabolism in peripheral tissues. Although the role of insulin in the periphery is well …

The role of NMDA receptors in Alzheimer's disease

J Liu, L Chang, Y Song, H Li, Y Wu - Frontiers in neuroscience, 2019 - frontiersin.org
In Alzheimer's disease (AD), early synaptic dysfunction is associated with the increased
oligomeric amyloid-beta peptide, which causes NMDAR-dependent synaptic depression …

[HTML][HTML] Deep multilayer brain proteomics identifies molecular networks in Alzheimer's disease progression

B Bai, X Wang, Y Li, PC Chen, K Yu, KK Dey… - Neuron, 2020 - cell.com
Alzheimer's disease (AD) displays a long asymptomatic stage before dementia. We
characterize AD stage-associated molecular networks by profiling 14,513 proteins and …

Implications of sleep disturbance and inflammation for Alzheimer's disease dementia

MR Irwin, MV Vitiello - The Lancet Neurology, 2019 - thelancet.com
Nearly half of all adults older than 60 years of age report sleep disturbance, as characterised
either by reports of insomnia complaints with daytime consequences, dissatisfaction with …

New insights into the pathogenesis of Alzheimer's disease

L Fan, C Mao, X Hu, S Zhang, Z Yang, Z Hu… - Frontiers in …, 2020 - frontiersin.org
Alzheimer's disease (AD), a common neurodegenerative disease in the elderly and the most
prevalent cause of dementia, is characterized by progressive cognitive impairment. The …

A review on advances of treatment modalities for Alzheimer's disease

ES Thoe, A Fauzi, YQ Tang, S Chamyuang, AYY Chia - Life sciences, 2021 - Elsevier
Alzheimer's disease (AD) is a multifactorial neurodegenerative disease which is mainly
characterized by progressive impairment in cognition, emotion, language and memory in …

Drug candidates in clinical trials for Alzheimer's disease

SY Hung, WM Fu - Journal of biomedical science, 2017 - Springer
Alzheimer's disease (AD) is a major form of senile dementia, characterized by progressive
memory and neuronal loss combined with cognitive impairment. AD is the most common …

Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions

A Abeysinghe, R Deshapriya, C Udawatte - Life sciences, 2020 - Elsevier
Alzheimer's disease (AD) is a neurodegenerative disorder and is identified as the most
common cause for dementia. Despite huge global economic burden and the impact on the …

Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease

JS Park, TI Kam, S Lee, H Park, Y Oh, SH Kwon… - Acta neuropathologica …, 2021 - Springer
Alzheimer's disease (AD) is the most common cause of age-related dementia. Increasing
evidence suggests that neuroinflammation mediated by microglia and astrocytes contributes …